Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.42
+5.9%		$3.03
$2.56
▼
$6.44
$665.25M0.184.27 million shs4.86 million shs
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$19.90
+0.3%		$21.40
$89.95
▼
$99.05
$576.80M0.9553,591 shs605,018 shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$0.68
-1.7%		$0.76
$0.53
▼
$2.35
$155.91M2.771.85 million shs1.20 million shs
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$6.89
-2.4%		$5.68
$4.75
▼
$12.23
$669.89M1.67193,764 shs22,866 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+5.88%+9.97%+12.87%+26.20%-7.07%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-7.24%-6.76%-7.03%+17.18%+160.50%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-1.74%-1.00%-12.93%-6.17%-42.10%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-2.41%+7.15%+31.74%+25.73%-21.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.42
+5.9%		$3.03
$2.56
▼
$6.44
$665.25M0.184.27 million shs4.86 million shs
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
$19.90
+0.3%		$21.40
$89.95
▼
$99.05
$576.80M0.9553,591 shs605,018 shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$0.68
-1.7%		$0.76
$0.53
▼
$2.35
$155.91M2.771.85 million shs1.20 million shs
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$6.89
-2.4%		$5.68
$4.75
▼
$12.23
$669.89M1.67193,764 shs22,866 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+5.88%+9.97%+12.87%+26.20%-7.07%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-7.24%-6.76%-7.03%+17.18%+160.50%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-1.74%-1.00%-12.93%-6.17%-42.10%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-2.41%+7.15%+31.74%+25.73%-21.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.67
Moderate Buy$14.33319.10% Upside
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
0.00
N/AN/AN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
2.86
Moderate Buy$4.00485.48% Upside
Valneva SE Sponsored ADR stock logo
VALN
Valneva
2.00
Hold$9.3034.98% Upside

Current Analyst Ratings Breakdown

Latest TNYA, VALN, ALT, and AVTE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
8/11/2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
7/28/2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/28/2026
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/2/2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Altimmune, Inc. stock logo
ALT
Altimmune
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/22/2026
Altimmune, Inc. stock logo
ALT
Altimmune
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$10.00
6/18/2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$31K21,459.73N/AN/A$2.44 per share1.40
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/A$3.96 per shareN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/A$0.31 per shareN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$197.56M3.31N/AN/A$0.99 per share6.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.09M-$0.78N/AN/AN/A-214,860.98%-31.41%-26.96%11/5/2026 (Estimated)
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$90.60M-$0.53N/AN/AN/AN/A-83.75%-66.53%11/11/2026 (Estimated)
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$130.33M-$2.11N/A15.66N/A-110.33%-153.20%-39.50%11/19/2026 (Estimated)

Latest TNYA, VALN, ALT, and AVTE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$0.1886-$0.40-$0.2114-$0.38$44.17 million$39.37 million
8/11/2026Q2 2026
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.1355-$0.12+$0.0155-$0.12$0.00 millionN/A
8/5/2026Q2 2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$0.0683-$0.20-$0.1317-$0.20$10.00 million$1.11 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/AN/AN/AN/AN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
0.07
26.78
26.78
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
8.78
8.78
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/A
4.52
4.52
Valneva SE Sponsored ADR stock logo
VALN
Valneva
2.04
2.16
1.69

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
N/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
90.54%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
11.39%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
1.60%
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
24.90%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
2.53%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
14.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
50194.52 million191.41 millionOptionable
Aerovate Therapeutics, Inc. stock logo
AVTE
Aerovate Therapeutics
2028.99 million21.69 millionOptionable
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
110224.23 million218.56 millionOptionable
Valneva SE Sponsored ADR stock logo
VALN
Valneva
70094.89 million80.74 millionNot Optionable

Recent News About These Companies

Valneva (NASDAQ:VALN) Trading Up 7.1% - Time to Buy?
September 2 at 12:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-valneva-nasdaq-valn-trading-up-71-time-to-buy-2026-09-02/
Valneva (NASDAQ:VALN) Shares Gap Up - Time to Buy?
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-valneva-nasdaq-valn-shares-gap-up-time-to-buy-2026-09-01/
Potential Moderna-style share surge? Takeover candidates Evotec, Valneva and Vidac Pharma in focus — analysts bullish
September 1, 2026  |  msn.comhttps://www.msn.com/en-ca/news/other/potential-moderna-style-share-surge-takeover-candidates-evotec-valneva-and-vidac-pharma-in-focus-analysts-bullish/ar-AA2bjBV0
Valneva's Property Sale Buys Breathing Room as Travel-Vaccine Demand Sours
August 30, 2026  |  ad-hoc-news.deA
Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Rating of "Hold" by Analysts
August 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30991571
Valneva's High-Wire Act: Can Cost Cuts and a Pivotal EMA Review Bridge the Gap to 2026?
August 29, 2026  |  ad-hoc-news.deA
Answers to 3 questions about a potential Lyme vaccine
August 28, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/answers-to-3-questions-about-a-potential-lyme-vaccine/ar-AA2b7FAB
Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Recommendation of "Hold" by Analysts
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-valneva-se-sponsored-adr-nasdaq-valn-given-consensus-recommendation-of-hold-by-analysts-2026-08-25/
Valneva's Regulatory Tailwind Collides With a Deepening Loss Profile
August 24, 2026  |  ad-hoc-news.deA
Valneva (NASDAQ:VALN) Shares Gap Down - Here's Why
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/valneva-nasdaqvaln-shares-gap-down-heres-why-2026-08-24/
Valneva's Analyst Divide Widens as EMA Review Puts Statistical Questions in the Spotlight
August 20, 2026  |  ad-hoc-news.deA
Valneva (VALN) Q2 2026 Earnings Call Transcript
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/valneva-valn-q2-2026-earnings-194457376.html
Research Analysts Issue Forecasts for Valneva Q3 Earnings
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/research-analysts-issue-forecasts-for-valneva-q3-earnings-2026-08-18/
EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine
August 17, 2026  |  pharmabiz.comP
EMA validates Pfizer and Valneva’s Lyme disease vaccine
August 17, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/ema-validates-pfizer-and-valneva-s-lyme-disease-vaccine/ar-AA2ajQPm
Pfizer, Valneva Lyme vaccine starts review in Europe
August 15, 2026  |  pharmaphorum.comP
Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance
August 15, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/valneva-shares-climb-after-lyme-disease-vaccine-receives-ema-application-acceptance-8a143cc5
Update: Valneva Shares Gain as Lyme Vaccine Candidate Gets EMA Review
August 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/valneva-shares-gain-lyme-vaccine-112557623.html
Valneva (NASDAQ:VALN) Issues Earnings Results, Misses Expectations By $0.17 EPS
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/valneva-nasdaqvaln-issues-earnings-results-misses-expectations-by-017-eps-2026-08-14/
Valneva (NASDAQ:VALN) Sees Strong Trading Volume - What's Next?
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/valneva-nasdaqvaln-sees-strong-trading-volume-whats-next-2026-08-14/
A Lyme disease vaccine may finally be on the way. Why did it take so long?
August 14, 2026  |  nationalpost.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illustration showing Hims & Hers logo and app connected through a security checkpoint icon to the Visa logo and card.
Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
By Jeffrey Neal Johnson | August 24, 2026
Server racks in a data center aisle with an overlaid digital network graphic and cloud icons above.
3 of the Market's Most-Upgraded Tech Stocks Right Now
By Ryan Hasson | August 10, 2026
Magnifying glass highlighting glowing candlestick chart bars against a dark background with an upward trending stock price line.
3 Overlooked Stocks Analysts Still Like as AI Trades Get Crowded
By Nathan Reiff | August 11, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Large outdoor display shows a declining red stock price chart amid downtown office towers with pedestrians walking nearby.
Asian Market Circuit Breakers Hit Stocks, Not AI Demand
By Jeffrey Neal Johnson | August 13, 2026
Altimmune stock logo

Altimmune NASDAQ:ALT

$3.42 +0.19 (+5.88%)
As of 09/4/2026 04:00 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Aerovate Therapeutics stock logo

Aerovate Therapeutics NASDAQ:AVTE

$19.90 +0.05 (+0.25%)
As of 09/4/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Tenaya Therapeutics stock logo

Tenaya Therapeutics NASDAQ:TNYA

$0.68 -0.01 (-1.74%)
As of 09/4/2026 04:00 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Valneva stock logo

Valneva NASDAQ:VALN

$6.89 -0.17 (-2.41%)
As of 09/4/2026 04:00 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas